Thanks for the link to that article KOO.
The second last sentence pretty much says it all, “When we’re trying to look for options for COVID-19, especially for treatment, we just have so few options,” With APB's safety profile, if we have good or great trial data it opens the gates for potentially very large sales. It gives us a much better understanding of why Eversana is staying around.
The comment in the second last paragraph about the effects on Long COVID taking months or years to prove is a little scary for us as that was in the description of what our PIII trial is about.
tada
